Oncoloxía médica
Servizo
Universidad de Córdoba
Córdoba, EspañaPublicacións en colaboración con investigadores/as de Universidad de Córdoba (16)
2024
-
Pancreatic cancer biomarkers: A pathway to advance in personalized treatment selection
Cancer Treatment Reviews, Vol. 125
2023
-
A signature of circulating microRNAs predicts the response to treatment with FOLFIRI plus aflibercept in metastatic colorectal cancer patients
Biomedicine and Pharmacotherapy, Vol. 159
2022
-
Effect of aflibercept plus FOLFIRI and potential efficacy biomarkers in patients with metastatic colorectal cancer: the POLAF trial
British Journal of Cancer, Vol. 126, Núm. 6, pp. 874-880
-
Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL study
European Journal of Cancer, Vol. 168, pp. 12-24
2021
-
Controversies in the treatment of RAS wild-type metastatic colorectal cancer
Clinical and Translational Oncology, Vol. 23, Núm. 4, pp. 827-839
-
First-Line Biological Agents Plus Chemotherapy in Older Patients with Metastatic Colorectal Cancer: A Retrospective Pooled Analysis
Drugs and Aging, Vol. 38, Núm. 3, pp. 219-231
-
Health-related quality of life with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor–positive metastatic breast cancer: Patient-reported outcomes in the PEARL study
European Journal of Cancer, Vol. 156, pp. 70-82
2020
-
FOLFOXIRI plus bevacizumab versus FOLFOX plus bevacizumab for patients with metastatic colorectal cancer and ≥3 circulating tumour cells: The randomised phase III VISNÚ-1 trial
ESMO Open, Vol. 5, Núm. 6
-
Serum phospholipids fatty acids and breast cancer risk by pathological subtype
Nutrients, Vol. 12, Núm. 10, pp. 1-18
2018
-
First-line mFOLFOX plus cetuximab followed by mFOLFOX plus cetuximab or single-agent cetuximab as maintenance therapy in patients with metastatic colorectal cancer: Phase II randomised MACRO2 TTD study
European Journal of Cancer, Vol. 101, pp. 263-272
-
Single-Agent Regorafenib in Metastatic Colorectal Cancer Patients with Any RAS or BRAF Mutation Previously Treated with FOLFOXIRI plus Bevacizumab (PREVIUM Trial)
Oncologist, Vol. 23, Núm. 11, pp. 1271-e128
2017
-
Incorporating BEAMing technology as a liquid biopsy into clinical practice for the management of colorectal cancer patients: An expert taskforce review
Annals of Oncology, Vol. 28, Núm. 12, pp. 2943-2949
2015
-
Epirubicin plus cyclophosphamide followed by docetaxel versus epirubicin plus docetaxel followed by capecitabine as adjuvant therapy for node-positive early breast cancer: Results from the GEICAM/2003-10 study
Journal of Clinical Oncology, Vol. 33, Núm. 32, pp. 3788-3795
-
Phase II trial of miniDOX (reduced dose docetaxel-oxaliplatin-capecitabine) in "suboptimal" patients with advanced gastric cancer (AGC). TTD 08-02
Cancer Chemotherapy and Pharmacology, Vol. 75, Núm. 2, pp. 319-324
2011
-
Fine mapping of a major histocompatibility complex in ankylosing spondylitis: Association of the HLA-DPA1 and HLA-DPB1 regions
Arthritis and Rheumatism, Vol. 63, Núm. 11, pp. 3305-3312
2010
-
Association of the KIR3DS1*013 and KIR3DL1*004 alleles with susceptibility to ankylosing Spondylitis
Arthritis and Rheumatism, Vol. 62, Núm. 4, pp. 1000-1006